Providence Medical Technology receives Australian regulatory approval: 4 insights

Written by Mackenzie Garrity | July 25, 2017 | Print  |

Providence Medical Technology received approval from the Australian Therapeutic Goods Administration for its DTRAX line of instruments and implants used in tissue sparing posterior cervical fusion.

Here are four insights:


1. DTRAX devices and instruments are designed to increase procedural efficiency, improve clinical outcomes, minimize complications and reduce recovery time.


2. In total, over 7,000 procedures using DTRAX devices and instruments have been used.


3. The company plans to submit the prosthesis list in August 2017 for inclusion into the market in early 2018.


4. Providence Medical Technology specializes in solutions for cervical spinal conditions. The company is a pioneer for tissue sparing approaches to posterior cervical fusions.


More articles on devices and implants:
Global bone growth stimulator market to hit $3.9B by 2025
ReNetX Bio initiates financing round for spinal cord injury technology trail: 7 highlights
Tissue Regenix proposes acquisition of CellRight Technologies: 4 notes

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months